Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 2.61M |
| Revenue (ttm) | 21.13M |
| Net Income (ttm) | -2.19M |
| Shares Out | 14.90M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 994,488 |
| Average Volume | 736,384 |
| Open | 0.1781 |
| Previous Close | 0.1782 |
| Day's Range | 0.1621 - 0.1816 |
| 52-Week Range | 0.1533 - 10.4000 |
| Beta | -0.03 |
| RSI | 31.86 |
| Earnings Date | Nov 14, 2025 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. Its accessories comprise HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; K5 tracer, a solution to perform continuous scanning of 3D surfaces; pushbutton panels; XPower digital drives for axis and spindle movement; and... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a Nectin-4 directed ant...
Shawn Hunsaker: Guiding New Businesses on an Effective Path with Strategic Vision
Shawn Leo Hunsaker, MBA, chief executive officer of Wolfe International Consulting LLC, is a leading expert in regulatory crisis management within the medical device industry. He specializes in helpin...
Merck (MRK) Gains FDA Approval for Keytruda in Bladder Cancer Treatment
Merck (MRK) Gains FDA Approval for Keytruda in Bladder Cancer Treatment
Merck gets FDA nod for Keytruda and Padcev combo in bladder cancer treatment
Merck (MRK) Gains FDA Nod for Keytruda Combination in Bladder Cancer
Merck (MRK) Gains FDA Nod for Keytruda Combination in Bladder Cancer
Elanco (ELAN) Gains FDA Emergency Use Authorization for Credelio CAT
Elanco (ELAN) Gains FDA Emergency Use Authorization for Credelio CAT
Elanco's Credelio CAT gets FDA Emergency Use Authorization
GOP-led states challenging FDA approval of generic abortion pill
Three Republican-led states have challenged the Food and Drug Administration’s (FDA) approval of a generic form of the abortion pill mifepristone earlier this year, arguing the agency’s decision had i...
Why Are Shares of Merck Up Today?
Shares of Merck & Company, Inc. (NASDAQ: MRK) are trading higher the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer. MRK shares are powering higher on stro...
Elanco (ELAN) Gains FDA Emergency Use Approval for Cat Treatment
Elanco (ELAN) Gains FDA Emergency Use Approval for Cat Treatment
Navi Mumbai: FDA to strictly enforce gutkha ban, says minister
Navi Mumbai: The Food and Drug Administration minister Narhari Jirwal said the state govt would tighten the ban on gutkha and consider action under th.
Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment
Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment
White House at odds with FDA Commissioner Makary top aide - report
FDA Chief Marty Makary resists White House pressure to remove top aide amid management disputes. Read more here.
Gilead (GILD) Unit Receives FDA Orphan Drug Designation
Gilead (GILD) Unit Receives FDA Orphan Drug Designation
HeartBeam (BEAT) Receives FDA Feedback; Roth Maintains Optimistic Outlook
HeartBeam (BEAT) Receives FDA Feedback; Roth Maintains Optimistic Outlook
The White House has asked for the resignation of a top aide to FDA chief
Commissioner Marty Makary is pushing back on the demand, sources told POLITICO, in the latest development to roil the agency
FDA Approves Merck's (MRK) Keytruda for Bladder Cancer Treatment
FDA Approves Merck's (MRK) Keytruda for Bladder Cancer Treatment
HeartBeam (BEAT) Faces FDA Setback for ECG Software Approval
HeartBeam (BEAT) Faces FDA Setback for ECG Software Approval
Merck Keytruda formulations approved in U.S. for bladder cancer
Merck (MRK) stock is in focus as the FDA approves its Keytruda versions with Pfizer (PFE) and Astellas' (ALPMF) Padcev for bladder cancer. Read more here.
FDA Investigates Fatality Linked to Takeda's (TAK) Adzynma Therapy
FDA Investigates Fatality Linked to Takeda's (TAK) Adzynma Therapy
Takeda blood disorder therapy Adzynma linked to patient death: FDA
Takeda Pharmaceutical (TAK) stock is in focus as the company's blood disease drug Adzynma is linked to a patient death, according to the FDA. Read more here.
FDA Approves New Indication for BioXcel Therapeutics' Igalmi (BTAI)
FDA Approves New Indication for BioXcel Therapeutics' Igalmi (BTAI)
Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission
Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission
FDA Raises Concerns Over Safety of Takeda's Adzynma (TAK)
FDA Raises Concerns Over Safety of Takeda's Adzynma (TAK)
Sangamo rises as FDA accepts rolling submission request for gene therapy
Sangamo Therapeutics (SGMO) stock rises as the U.S. FDA accepts a rolling submission request for the firm's ST-920 gene therapy targeting Fabry disease. Read more here.